Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1140)	5/12/1998 2:21:00 PM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

Rudy, Agreed, IL-1 has potential. Why then does the stock have a market value of 16 cents? When it has 60 cents a share in cash...and IL-1? Anyone know of ANY biotech big or small trading at a 1/4 cash? If you do please post.

To: Rudy Saucillo who wrote (1140)	5/12/1998 2:29:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2742

Thanks, Rudy. Good stuff. Don't know if you saw it, but there was also a follow-up abstract from Levy/Stanford. I posted it here for Brucie. Brucie.... I can find it and post it here again, if you like. Carney?? Carney, Carney, Carney??

To: Rudy Saucillo who wrote (1140)	6/5/1998 2:09:00 PM
From: Rudy Saucillo	Read Replies (2) \| Respond to of 2742

Comments from the technical experts? This recent study showed that IL-1b used as an adjuvant with a mannan fusion protein vaccine "enhanced antibody responses to levels fourfold that induced by M-FP alone without adversely affecting the cytotoxic activity induced by M-FP immunization." Rudy Vaccine 1997 Oct;15(14):1586-1593 Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Lofthouse SA, Apostolopoulos V, Pietersz GA, Li W, McKenzie IF Austin Research Institute, Heidelberg, Vic., Australia. Effective vaccination-based control of intracellular pathogens or parasites and various tumours is dependent upon induction of cytotoxic lymphocytes and other mechanisms of cellular immunity. Such responses are usually described as being antagonistic to an antibody-based immune response. This paper elaborates on previous studies that have demonstrated that conjugation of a fusion protein (FP, incorporating copies of the variable number of tandem repeat sequence of human mucin-1 (MUC1)) to oxidized mannan results in a significant shift from a type-2 response towards a type-1 response. This response induces complete protection upon challenge of immunized mice with MUC1 expressing tumour cells. This report details experiments in which the balance between type-1 and type-2 anti-MUC1 responses is manipulated by altering the dose of mannan-FP (M-FP) delivered. It is also shown that type-1 and type-2 responses may be induced simultaneously by administration of both forms of the antigen (FP/M-FP). Further, when a type-2 response is induced after FP immunization, a type-1 response can also be established by subsequent immunization with M-FP without adversely affecting the initial response. The converse also applies when M-FP is used for the initial immunizations, followed by FP administration. Delivery of interleukin-1 beta as a cytokine adjuvant with M-FP immunizations also enhanced antibody responses to levels fourfold that induced by M-FP alone without adversely affecting the cytotoxic activity induced by M-FP immunization. Contrary to the type-1/type-2 paradigm, cellular and antibody responses to MUC1 were not antagonistic. These results have important implications for the development of vaccination strategies against pathogens for which both the cellular and humoral compartments of the immune response contribute to protection.